Environmental and NSAID-enteropathy: Dysbiosis as a common factor

Current Gastroenterology Reports

Volumn 16, Issue 3, 2014, Pages

  Syer, Stephanie D ^a   Wallace, John L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bacteria; Bleeding; Dysbiosis; Intestine; Malabsorption; Microbiome; Nonsteroidal anti inflammatory drug; Probiotic; Proton pump inhibitor; Ulcer

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LACTOBACILLUS ACIDOPHILUS PROBIOTIC AGENT; LACTOBACILLUS ADOLESCENTIS PROBIOTIC AGENT; LACTOBACILLUS CASEI PROBIOTIC AGENT; LACTOBACILLUS RHAMNOSUS PROBIOTIC AGENT; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; REBAMIPIDE; RETINOL; UNCLASSIFIED DRUG; ZINC;

CAPSULE ENDOSCOPY; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOUBLE BALLOON ENTEROSCOPY; DRUG INDUCED DISEASE; DYSBIOSIS; ENTERITIS; ENTEROPATHY; ENVIRONMENTAL ENTEROPATHY; HUMAN; INTESTINE FUNCTION; MALNUTRITION; NOMENCLATURE; NONHUMAN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS INDUCED ENTEROPATHY; REVIEW; ENVIRONMENTAL EXPOSURE; MICROBIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSBIOSIS; ENVIRONMENTAL EXPOSURE; HUMANS; INTESTINAL DISEASES; PROBIOTICS;

EID: 84893639935     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0377-1     Document Type: Review

References (47)

1. Bartram J, Cairncross S. Hygiene, sanitation, and water: Forgotten foundations of health. PLoS Medicine. 2010;7(11):e1000367.
2. Lin A, Arnold BF, Afreen S, Goto R, Huda TM, Haque R, et al. Household environmental conditions are associated with enteropathy and impaired growth in rural Bangladesh. The American Journal of Tropical Medicine and Hygiene. 2013;89:130-7.
3. Ramakrishna BS, Venkataraman S, Mukhopadhya A. Tropical malabsorption. Postgrad Med J. 2006;82:779-87. (Pubitemid 46101924)
4. Calder PC, Krauss-Etschmann S, de Jong EC, Dupont C, Frick JS, Frokiaer H, et al. Early nutrition and immunity - progress and perspectives. The British Journal of Nutrition. 2006;96(4):774-90. (Pubitemid 46470203)
5. Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet. 2009;374(9694):1032-5.
6. Lindenbaum J. Small intestine dysfunction in Pakistanis and Americans resident in Pakistan. The American Journal of Clinical Nutrition. 1968;21(9):1023-9.
7. McKay S, Gaudier E, Campbell DI, Prentice AM, Albers R. Environmental enteropathy: New targets for nutritional interventions. International Health. 2010;2(3):172-80.
8. Thurnham DI, Northrop-Clewes CA, McCullough FS, Das BS, Lunn PG. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants. The Journal of Infectious Diseases. 2000;182 Suppl 1:S23-8.
9. Chen P, Soares AM, Lima AA, Gamble MV, Schorling JB, Conway M, et al. Association of vitamin A and zinc status with altered intestinal permeability: Analyses of cohort data from northeastern Brazil. Journal of Health, Population, and Nutrition. 2003;21:309-15. (Pubitemid 38332084)
10. Williams EA, Elia M, LUNN PG. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering Gambian infants. Am J Clin Nutr. 2007;86:421-7. (Pubitemid 47256927)
11. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005;21:44.
12. Galpin L, Manary MJ, Fleming K, Ou CN, Ashorn P, Shulman RJ. Effect of lactobacillus GG on intestinal integrity in Malawian children at risk of tropical enteropathy. The American Journal of Clinical Nutrition. 2005;82:1040-5. (Pubitemid 43779762)
13. Trehan I, Shulman RJ, Ou CN, Maleta K, Manary MJ. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. Am J Gastroenterol. 2009;104:2326-33.
14. Bjarnason I, Price AB, Zanelli G, Smethurst P, Burke M, Gumpel JM, et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology. 1988;94:1070-4.
15. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-9. (Pubitemid 40092944)
16. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-8.
17. .• Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009; 104: 1633-1641. This paper provides compelling evidence for a steady decline in upper GI adverse effects of NSAIDs after introduction of inhibitors of gastric acid secretion, but at a cost of a significant increase in the incidence of damage in the lower GI tract.
18. Endo H, Sakai E, Higurashi T, Yamada E, Ohkubo H, Iida H, et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44:833-8.
19. Wallace JL. (2012) NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012;165:67-74.
20. Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol. 1969;54:237-49.
21. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol. 1996;40:553-60. (Pubitemid 26282108)
22. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti- inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997;112:109-17. (Pubitemid 27008992)
23. Kinouchi T, Kataoka K, Bing SR, Nakayama H, Uejima M, Shimono K, et al. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiol Immunol. 1998;42:347-55. (Pubitemid 28232211)
24. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J Med Invest. 2004;51:43-51. (Pubitemid 38899321)
25. Brune K, Dietzel K, Nurnberg B, Schneider HT. Recent insight into the mechanism of gastrointestinal tract ulceration. Eur J Rheumatol Inflamm. 1987;9:8-14. (Pubitemid 18059060)
26. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19:1861-76.
27. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol. 2001;16:1112-9. (Pubitemid 32990106)
28. Syer SD, McKnight W, Aucouturier A, Martin R, Langella P, Wallace JL. (2012) Bifidobacteria exert a protective effect against NSAID-induced enteropathy that is dependent on lactate production. Gastroenterology 142, S-489.
29. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3-10. (Pubitemid 43381161)
30. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during pro- ton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8: 504-8.
31. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15: 573-4.
32. Andreasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med. 2011;270:50-7.
33. •Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, et al. (2011) Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141, 1314-1322. First demonstration that proton pump inhibitors exacerbate NSAID-induced intestinal damage. This study also showed that the underlying mechanism was a PPI-induced loss of Bifidobacteria in the intestine.
34. .• Satoh H, Amagase K, Takeuchi K. (2012) Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 343, 270-277. Confirmation that suppression of gastric acid secretion results in exacerbation of small intestinal damage induced by NSAIDs, and evidence for a role of disturbed motility in the generation of the injury.
35. Brown WR, Tayal S. Microscopic colitis. A review J Dig Dis. 2013;14:277-81.
36. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599-608.
37. Ananthakrishnan AN. Environmental triggers for inflammatory bowel disease. Gastroenterol Hepatol (NY). 2013;9:367-74.
38. Morris AJ, Murray L, Sturrock RD, Madhok R, Capell HA, Mackenzie JF. Short report: the effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther. 1994;8:343-6. (Pubitemid 24205535)
39. Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339-46.
40. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1989;34:407-11. (Pubitemid 19088782)
41. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation. 1993;17:641-62. (Pubitemid 23359088)
42. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33:1204-8.
43. Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double- blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol. 2011;46:57-64.
44. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, et al. Efficacy of rebamipide for diclofenac- induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo- controlled, cross-over study. J Gastroenterol. 2008;43:270-6. (Pubitemid 351650037)
45. Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti- inflammatory drug enteropathy - a randomized, double- blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther. 2010;32:209-14.
46. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol. 2011;46:894-905.
47. Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol. 2009;297:G506-13.